Inhibitor

Bibliography

Biblio print

Tree Display

AceDB Schema

XML Display

Feedback

Inhibitor Report for: Rilapladib

Rilapladib	Type	Trifluoro
		Piperidine
		Sulfur Compound
	Other_Name	UNII-O14CWE893Z
		Rilapladib (USAN)
		SB 659032
		SB659032
		D05728
		DB05119
	Chemical_Nomenclature	2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]-N-[1-(2-methoxyethyl)piperidin-4-yl]-N-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide
	Formula	C40H38F5N3O3S
	CAS_number	412950-08-4
	MW	735.80
	Paper (6)
	Comment	Rilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development. It is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques.
	Gene_locus	human-PLA2G7
	CID	9918381
	Family	PAF-Acetylhydrolase
	InChIKey	NNBGCSGCRSCFEA-UHFFFAOYSA-N
	CanonicalSMILES	COCCN1CCC(CC1)N(CC2=CC=C(C=C2)C3=CC=C(C=C3)C(F)(F)F)C(=O)CN4C5=CC=CC=C5C(=O)C=C4SCC6=C(C(=CC=C6)F)F
	InChI	InChI=1S/C40H38F5N3O3S/c1-51-22-21-46-19-17-32(18-20-46)47(24-27-9-11-28(12-10-27)29-13-15-31(16-14-29)40(43,44)45)37(50)25-48-35-8-3-2-6-33(35)36(49)23-38(48)52-26-30-5-4-7-34(41)39(30)42/h2-16,23,32H,17-22,24-26H2,1H3
	IupharLig	7376